CELESTIMO Meets Its Phase III PFS Endpoint

Company Roche / Genentech Event Type Phase III Interim Analysis (Primary Endpoint Met) Modality CD20×CD3 Bispecific Antibody Plus Immunomodulatory Agent Asset Mosunetuzumab Plus Lenalidomide Disease Area Relapsed or Refractory Follicular Lymphoma Summary The Phase III CELESTIMO study met its primary progression-free-survival endpoint at an interim…